11/9/2006

The FDA needs to do more to protect the safety of kidney dialysis patients who are given high doses of the anemia drug Epogen in clinics, says Dr. Ajay Singh, a clinical chief of the renal division at Brigham and Women's Hospital. Singh, a researcher whose trial of a similar drug had to be halted last year because of safety issues, said there is a trend of higher dosing for dialysis patients and the FDA needs to intervene.

Related Summaries